Answers are grounded in this paper and cite their sources.
Asthma and chronic obstructive pulmonary disease (COPD) affect millions worldwide, posing major concerns for global healthcare systems. The positioning of fluticasone furoate/vilanterol (FF/Vi) in the treatment paradigm of these respiratory conditions among diverse patient profiles in India remains unclear. Therefore, this consensus aims to address gaps in the strategic positioning of FF/Vi in asthma and COPD treatment in India. A two-round modified Delphi method involving 11 subject matter experts was employed to develop consensus statements and recommendations on treating asthma and COPD patients. Fourteen consensus statements were finalized, addressing the safety, efficacy, and potential use of FF/Vi in various patient populations with asthma and COPD. Key findings indicated that FF/Vi reduces exacerbations and improves symptoms in patients with cardiovascular comorbidities. Its once-daily dosing regimen enhances treatment adherence, particularly in non-compliant patients. Fluticasone furoate/vilanterol also shows promise in improving symptoms across different asthma severities and age groups and enhancing pulmonary function. In COPD, FF/Vi is non-inferior to conventional therapies, improves health status, reduces exacerbations, and offers long-term relief. The consensus statements provide actionable insights for clinicians to optimize treatment strategies for asthma and COPD patients in India. Future research should focus on validating these recommendations and addressing existing limitations in the evidence base. Not applicable.
No takes yet. Share an insight, caveat, or question.
Talwar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: